ARO-MAPT Shows Deep CSF Tau Knockdown
Arrowhead reported interim Phase 1/2a data showing dose-dependent and durable cerebrospinal-fluid total-tau reductions after subcutaneous ARO-MAPT in healthy volunteers. Mean reduction at day 105 reached 73% at 12.8 mg/kg, with a maximum individual reduction…
